Detection of high-risk thrombophilia with an automated, global test: the Coagulation Inhibitor Potential assay.

The diagnosis of thrombophilia is a cost-consuming and time-consuming process, as each defect should be separately investigated. The Coagulation Inhibitor Potential (CIP) assay is a promising new global test, sensitive for most of the hereditary thrombophilias, developed for manual methodology. We adapt the original method to an optical coagulation analyser. By this automation, the test will be easier, faster and more precise, and it also allows carrying out 18 measurements simultaneously. The CIP assay was performed in 126 healthy subjects and 193 patients with different types of hereditary thrombophilia conditions. Detected with conventional laboratory tests high-risk thrombophilia was present in 70 patients: deficiencies of antithrombin (AT) (n=12), protein C (PC) (n=14), protein S (PS) (n=6), homozygous factor V Leiden (FVL) mutation (n=9) and combined types (n=29). Low-risk thrombophilia was present in 123 patients: heterozygous FVL (n=115) and FII G2010A mutation (n=8). Significantly lower median CIP values were found for AT-,PC-, PS deficiencies, homozygous and heterozygous FVL mutations and combined thrombophilias (P<0.01) as compared with healthy controls. There was no significant difference between the heterozygous FIIG20210A (P=0.669) thrombophilia group and the healthy controls. The best performance of the test was achieved at the cut-off value of 90.0U (area: 0.981) with 96% sensitivity and 92% specificity in the high-risk thrombophilia group estimated by receiver operating characteristic analysis. The new method seems to be appropriate and reliable for the detection of AT-, PC- and PS deficiencies, homozygous FVL mutation and also for combined deficiencies. The automated CIP test is insensitive to FII G2010A mutation.